[go: up one dir, main page]

AU2001274954A1 - Compositions and methods for delivery of a molecule into a cell - Google Patents

Compositions and methods for delivery of a molecule into a cell

Info

Publication number
AU2001274954A1
AU2001274954A1 AU2001274954A AU7495401A AU2001274954A1 AU 2001274954 A1 AU2001274954 A1 AU 2001274954A1 AU 2001274954 A AU2001274954 A AU 2001274954A AU 7495401 A AU7495401 A AU 7495401A AU 2001274954 A1 AU2001274954 A1 AU 2001274954A1
Authority
AU
Australia
Prior art keywords
molecule
delivery
compositions
cell
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001274954A
Inventor
Carlos M. C. De Noronha
Warner C. Greene
Peter Henklein
Ulrich Schubert
Michael P. Sherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
J David Gladstone Institutes
Original Assignee
J David Gladstone Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J David Gladstone Institutes filed Critical J David Gladstone Institutes
Publication of AU2001274954A1 publication Critical patent/AU2001274954A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16311Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2001274954A 2000-05-23 2001-05-23 Compositions and methods for delivery of a molecule into a cell Abandoned AU2001274954A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US20661000P 2000-05-23 2000-05-23
US60/206,610 2000-05-23
US26782701P 2001-02-09 2001-02-09
US60/267,827 2001-02-09
US09/839,329 US6664040B2 (en) 2000-05-23 2001-04-20 Compositions and methods for delivery of a molecule into a cell
US09/839,329 2001-04-20
PCT/US2001/016943 WO2001090159A2 (en) 2000-05-23 2001-05-23 Compositions and methods for delivery of a molecule into a cell

Publications (1)

Publication Number Publication Date
AU2001274954A1 true AU2001274954A1 (en) 2001-12-03

Family

ID=27394962

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001274954A Abandoned AU2001274954A1 (en) 2000-05-23 2001-05-23 Compositions and methods for delivery of a molecule into a cell

Country Status (6)

Country Link
US (1) US6664040B2 (en)
EP (1) EP1290017A2 (en)
JP (1) JP2004501111A (en)
AU (1) AU2001274954A1 (en)
CA (1) CA2407570A1 (en)
WO (1) WO2001090159A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1351980B1 (en) * 2001-01-18 2014-12-31 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
FR2827866B1 (en) * 2001-07-27 2004-12-10 Pasteur Institut SYNTHETIC OR NATURAL PEPTIDES BINDING PROTEIN PHOSPHATASE 2A, IDENTIFICATION METHOD AND USES
US20040191843A1 (en) * 2003-02-03 2004-09-30 Palo Alto Institute Of Molecular Medicine Cell-killing molecules and methods of use thereof
WO2014123614A2 (en) * 2012-12-06 2014-08-14 Theusa, As Represented By The Secretary Of The Army On Behalf Of The Us Army Mri Infectious Diseases Antiviral rift valley fever virus virus peptides and methods of use
WO2014169274A2 (en) 2013-04-12 2014-10-16 Yale University Modified proteins and methods of use thereof
SG11201604697TA (en) 2013-12-12 2016-07-28 Life Technologies Corp Membrane-penetrating peptides to enhance transfection and compositions and methods for using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108707A (en) 1993-02-19 1999-06-20 Weiner David B Pharmaceutical compositions and diagnostic kits comprising hiv protein vpr or proteins that bind to vpr
EP0753006A4 (en) 1994-03-25 1999-04-14 Biomolecular Res Inst Ltd Vpr AND Vpx PROTEINS OF HIV
US5861161A (en) 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
US5763190A (en) * 1994-09-21 1998-06-09 The Trustees Of The University Of Pennsylvania Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein
EP0873415B1 (en) 1995-04-14 2008-09-10 University Of Alabama Research Foundation Fusion protein delivery system and uses thereof
US6087486A (en) 1996-01-29 2000-07-11 The Trustees Of The University Of Pennsylvania Nucleotide sequences encoding vpr receptor protein
AU6333598A (en) 1997-02-11 1998-08-26 Regents Of The University Of California, The Methods of inducing cell cycle stasis
US6221355B1 (en) 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
EP1155035A2 (en) 1999-02-19 2001-11-21 Ulrich Schubert Synthetic peptide of regulatory virus protein r (vpr) of human immunodeficiency virus type 1 (hiv-1) and the utilization thereof

Also Published As

Publication number Publication date
WO2001090159A3 (en) 2002-06-13
WO2001090159A2 (en) 2001-11-29
CA2407570A1 (en) 2001-11-29
US20020022027A1 (en) 2002-02-21
JP2004501111A (en) 2004-01-15
US6664040B2 (en) 2003-12-16
WO2001090159B1 (en) 2002-09-26
EP1290017A2 (en) 2003-03-12

Similar Documents

Publication Publication Date Title
AU2001278877A1 (en) A composition for the delivery of live cells and methods of use
AU2001280767A1 (en) Peptide-mediated delivery of molecules into cells
AU2001259846A1 (en) Methods and compositions for enhancing the delivery of a nucleic acid to a cell
AU2001285143A1 (en) Methods and compositions for targeted delivery
AU2001273034A1 (en) Composition for delivery of hematopoietic growth factor
AU781269C (en) Pharmaceutical compositions
AU2001250420A1 (en) Pharmaceutical compositions
AU2001258801A1 (en) Gelling composition
AU2001274307A1 (en) Pharmaceutical compositions
AU2001270256A1 (en) Cubic liquid crystalline compositions and methods for their preparation
AU5326100A (en) Pharmaceutical compositions and methods for use
AU2001271502A1 (en) Methods and compositions for isolating biologically active antibodies
AU2001232020A1 (en) Floating drug delivery composition
AU2001288395A1 (en) Method for enhanced delivery of oxybutynin and compositions thereof
AU2001290239A1 (en) Medicinal composition
AU2001238485A1 (en) Methods and compositions for gene delivery
AU2001273919A1 (en) Pharmaceutical compositions
AU2001274954A1 (en) Compositions and methods for delivery of a molecule into a cell
AU2001261732A1 (en) Composition for delivery of compounds to cells
AU4800800A (en) Fuel compositions
AU6094200A (en) Nor gene compositions and methods for use thereof
AU2844801A (en) Fuel compositions
AU4085201A (en) Pharmaceutical composition
AU3926000A (en) Methods and compositions for drug delivery
AU9517501A (en) Composition containing leishmania LIP2A